文献速递艾滋病与性传播感染

博茨瓦纳多替拉韦一线抗逆转录病毒治疗者低水平病毒血症与空间异质性:2016-2022年全国性研究

Low-Level Viremia and Spatial Heterogeneity Among Individuals on Dolutegravir-Based Antiretroviral Therapy in Botswana: A Nationwide Study (2016-2022).
PubMed 文献 · J Infect Dis · 2026-01-01

可检测病毒血症定义为病毒载量(VL)>50拷贝/mL,并分为低水平病毒血症(LLV;51-999拷贝/mL)和病毒学失败(VF;≥1000拷贝/mL)。结果显示可检测病毒血症率从2017年6.7%升至2021年13.5%(P<.001),LLV odds每年增加50%,VF odds每年下降6%;男性(aOR 1.36 [95%CI 1.30-1.43])和农村居住(aOR 1.10 [95%CI 1.05-1.16])与更高odds持续相关。

要点

  • DTG一线ART中可检测病毒血症率2017-2021年从6.7%升至13.5%,LLV odds每年增加50%。
  • 男性(aOR 1.36)和农村居住(aOR 1.10)与可检测病毒血症、LLV和VF更高odds持续相关。
  • VF odds每年下降6%,但LLV上升,需针对高风险人群和地区实施靶向干预。

核心结论

  • 尽管病毒学失败(VF)在下降,但低水平病毒血症(LLV)在上升。
  • 可检测病毒血症存在空间异质性,男性、农村居住者和年轻个体(18-35岁)odds更高。
  • 需对高风险群体和地区实施靶向干预以进一步抑制病毒血症并实现持续疫情控制。

研究设计与样本

  • 可检测病毒血症定义为VL>50拷贝/mL,分为LLV(51-999拷贝/mL)和VF(≥1000拷贝/mL)。
  • 采用广义估计方程(GEE)模型评估可检测病毒血症的odds,并按年份和地区分层映射。

主要发现

  • 可检测病毒血症率:2017年6.7%、2018年5.6%、2019年4.7%、2020年7.1%、2021年13.5%、2022年11.2%(P<.001)。
  • 线性年度趋势显示,自2017年起每增加一年,可检测病毒血症odds增加23%,LLV odds增加50%,VF odds下降6%。
  • 重复测量GEE模型显示男性(aOR 1.36 [95%CI 1.30-1.43])和农村居住(aOR 1.10 [95%CI 1.05-1.16])与可检测病毒血症、LLV和VF更高odds持续相关。

临床怎么用

  • 对接受DTG一线ART的HIV感染者,应关注LLV上升趋势,尤其男性、农村居住和年轻个体(18-35岁)。
  • 可利用空间分析识别可检测病毒血症高负担地区,指导靶向干预资源配置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The study uses spatial analysis to identify factors associated with human immunodeficiency virus (HIV) detectable viremia in dolutegravir (DTG)-based first-line antiretroviral therapy (ART), which is crucial for targeted interventions to sustain epidemic control in Botswana. METHODS: This was a longitudinal observational cohort utilizing a dataset of 42 546 people with HIV on DTG-based first-line ART from June 2016 to December 2022 enrolled in the Botswana National Treatment Program. Detectable viremia was defined as viral load (VL) >50 copies/mL and further classified into low-level viremia (LLV; VL from 51 to 999 copies/mL) and virologic failure (VF; VL ≥1000 copies/mL). The rates of detectable viremia, LLV, and VF were stratified by year from 2017 to 2022 and mapped by districts in Botswana. Generalized estimating equation (GEE) models were utilized to evaluate odds of detectable viremia. RESULTS: There was an overall trend of increasing detectable viremia, with rates of 6.7% (2017), 5.6% (2018), 4.7% (2019), 7.1% (2020), 13.5% (2021), and 11.2% (2022) (P < .001). The linear annual trend showed that each additional year from 2017 was associated with 23% increased odds of detectable viremia and 50% increase in the odds of LLV, while odds of VF decreased by 6% per year. Repeated-measures GEE models showed that male sex (adjusted odds ratio [aOR], 1.36 [95% confidence interval {CI}, 1.30-1.43]) and rural residence (aOR, 1.10 [95% CI, 1.05-1.16]) were consistently associated with higher odds of detectable viremia, LLV, and VF over follow-up. CONCLUSIONS: While VF is declining, LLV is increasing. We observed spatial heterogeneity in detectable viremia, and higher odds in males, those with rural residence, and young individuals (18-35 years). Targeted interventions are necessary for high-risk groups and regions to further suppress viremia and achieve sustained epidemic control beyond the UNAIDS 95-95-95 targets.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Choga OT, Matsena-Zingoni Z, Choga WT, et al. Low-Level Viremia and Spatial Heterogeneity Among Individuals on Dolutegravir-Based Antiretroviral Therapy in Botswana: A Nationwide Study (2016-2022). J Infect Dis. 2026. PMID: 42605207. doi:10.1093/infdis/jiag364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。